{
    "clinical_study": {
        "@rank": "134358", 
        "acronym": "COMPLETE", 
        "arm_group": [
            {
                "arm_group_label": "Multi-vessel revascularization", 
                "arm_group_type": "Active Comparator", 
                "description": "Additional PCI for non-culprit lesions"
            }, 
            {
                "arm_group_label": "Medical Therapy", 
                "arm_group_type": "No Intervention", 
                "description": "Optimal medical therapy as per current guidelines"
            }
        ], 
        "brief_summary": {
            "textblock": "To determine whether, on a background of optimal medical therapy, including ticagrelor,\n      opening of all suitable narrowings or blockages found at the time of primary PCI for an\n      acute heart attack is better than treating only the culprit lesion in patients with\n      multi-vessel disease."
        }, 
        "brief_title": "Complete vs Culprit-only Revascularization to Treat Multi-vessel Disease After Primary PCI for STEMI", 
        "completion_date": {
            "#text": "December 2018", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Acute Myocardial Infarction", 
            "Coronary Artery Disease", 
            "Percutaneous Coronary Intervention"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Coronary Disease", 
                "Infarction", 
                "Myocardial Infarction"
            ]
        }, 
        "detailed_description": {
            "textblock": "To determine whether, on a background of optimal medical therapy with low-dose ASA and\n      ticagrelor, a strategy of complete revascularization involving staged PCI using drug eluting\n      stents of all suitable non-infarct related artery lesions is superior to a strategy of\n      culprit lesion-only revascularization in reducing the composite outcome of CV death or MI in\n      patients with multi-vessel disease who have undergone successful culprit lesion primary PCI\n      for STEMI."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Men and women within 72 hours after successful PCI (preferably using a drug eluting\n             stent) to the culprit lesion for STEMI.  PCI for STEMI can be either primary PCI or\n             rescue PCI for failed fibrinolysis or a combination strategy where PCI is performed\n             routinely 3-12 hours after fibrinolysis AND\n\n          2. Multi-vessel disease defined as at least 1 additional non-infarct related coronary\n             artery lesion that is at least 2.5 mm in diameter that has not been stented as part\n             of the primary PCI and that is amenable to successful treatment with PCI and has:\n\n               -  At least 70% diameter stenosis (visual estimation) or\n\n               -  At least 50% diameter stenosis (visual estimation) with fractional flow reserve\n                  (FFR) \u2264 0.80\n\n        Exclusion Criteria:\n\n          1. Planned revascularization of non-culprit lesion\n\n          2. Planned surgical revascularization\n\n          3. Non-cardiovascular co-morbidity reducing life expectancy to < 5 years\n\n          4. Any factor precluding 5 year follow-up\n\n          5. Prior Coronary Artery Bypass Graft (CABG) Surgery"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "3900", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 27, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01740479", 
            "org_study_id": "COMPLETE-2012"
        }, 
        "intervention": {
            "arm_group_label": "Multi-vessel revascularization", 
            "description": "Additional PCI procedure", 
            "intervention_name": "PCI for non-culprit lesions", 
            "intervention_type": "Procedure"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "STEMI", 
            "ticagrelor", 
            "multi-vessel disease", 
            "culprit lesion"
        ], 
        "lastchanged_date": "April 24, 2013", 
        "location": {
            "contact": {
                "email": "smehta@mcmaster.ca", 
                "last_name": "Shamir Mehta, MD", 
                "phone": "905-527-4322"
            }, 
            "facility": {
                "address": {
                    "city": "Hamilton", 
                    "country": "Canada", 
                    "state": "Ontario", 
                    "zip": "L8L2X2"
                }, 
                "name": "Hamilton General Hospital"
            }, 
            "investigator": {
                "last_name": "Shamir Mehta, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized Comparative Effectiveness Study of Complete vs Culprit-only Revascularization Strategies to Treat Multi-vessel Disease After Primary Percutaneous Coronary Intervention (PCI) for ST-segment Elevation Myocardial (STEMI) Infarction", 
        "other_outcome": {
            "measure": "Major Bleeding", 
            "safety_issue": "Yes", 
            "time_frame": "Over duration of follow-up (average of approximately 4 years)"
        }, 
        "overall_contact": {
            "email": "complete@phri.ca", 
            "last_name": "Research Coordinator, BSc, MSc", 
            "phone": "1-866-414-7474"
        }, 
        "overall_official": {
            "affiliation": "McMaster University", 
            "last_name": "Shamir R Mehta, MD, MSc", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Canada: Population Health Research Institute and individual hospital IRB's", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Composite of Cardiovascular death or new myocardial Infarction", 
            "safety_issue": "No", 
            "time_frame": "over duration of follow-up (average of approximately 4 years)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01740479"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Population Health Research Institute", 
            "investigator_full_name": "Dr. Shamir Mehta", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Composite of CV death, new MI, ischemia-driven revascularization or hospitalization for unstable angina or heart failure", 
            "safety_issue": "No", 
            "time_frame": "Over duration of follow-up (average of approximately 4 years)"
        }, 
        "source": "Population Health Research Institute", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Population Health Research Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}